First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan
{{output}}
Background/aim: Afatinib is an irreversible EGFR-TKI effective against uncommon EGFR mutations in non-small cell lung cancer (NSCLC), but the influence of mutation subtype and starting dose on treatment outcomes remains unclear. ... ...
